The headquarters of Eli Lilly in Indianapolis, Ind., on March 17, 2024. Scott Olson/Getty ImagesEli Lilly and Company announced on April 20 that it will acquire clinical-stage cancer biotechnology company Kelonia Therapeutics for $7 billion.The acquisition expands Eli Lilly’s pipeline into experimental cancer treatments, specifically in vivo genetic therapy. Kelonia Therapeutics is advancing CAR-T genetic medicines that reprogram a cancer patient’s T-cells to fight cancer and underlying diseases. Its lead program, KLN-1010, targets cancerous myeloma plasma cells that affect bone marrow.
Eli Lilly Buys Kelonia Therapeutics for $7 Billion to Boost Cancer Treatment Pipeline
Related Articles
BusinessCompaniesEnergy
EQT to Buy Range Resources, Creating Largest US Natural Gas Producer
EQT Corp. has agreed to acquire rival Appalachian shale driller Range Resources...
BrightBusinessInvestingPersonal FinanceStocks
Wall Street Is Very NervousShould You Worry? Can You Repair Your Losses?
On Oct. 23, the Dow Jones Industrial Average fell 652.82 points, or...
BusinessMarkets
Nearly 3 in 10 New-Car Trade-Ins Are Underwater, Edmunds Finds
Almost three in 10 vehicles traded toward a new car are worth...
Asia & PacificChina NewsEuropeInternational RelationsNational SecurityPolicies & ImpactsUSUS NewsUS-China RelationsWorld News
Japan Defense Academy Chief Calls for 3 Red Lines in Competition With China
Japan’s former top uniformed military officer has called for establishing three “red...
